Updated May 30, 2026, 4:23 PM
Calcium channel blocker, antianginal, antihypertensiveUS FDA Database Verified

niCARdipine (Rx)

Generic: NiCARdipine

Brand: Cardene IV, Cardene SR

(nye- card'i- peen)

Pregnancy Category: C

Pharmacological Action

Inhibits calcium ion influx across cell membrane during cardiac depolarization, produces relaxation of coronary vascular smooth muscle and peripheral vascular smooth muscle, dilates coronary arteries, increases myocardial oxygen delivery in patients with vaso- spastic angina

Therapeutic outcome: Decreased angina pectoris, decreased B/P in hypertension

Uses

Chronic stable angina pectoris, hypertension

Contraindications

Sick sinus syndrome, 2 nd- or 3 rd- degree heart block, hypersensitivity to this product or dihydropyridine, advanced aortic stenosis

Precautions: Pregnancy C, breastfeeding, children, geriatric, CHF, hypotension, hepatic injury, renal disease

Dosage & Routes

Hypertension

Adult: PO 20 mg tid initially; may increase after 3 days (range 20- 40 mg tid) or SUS REL 30 mg bid; may increase to 60 mg bid IV 5 mg/hr; may increase by 2.5 mg/hr q15 min; max 15 mg/hr Angina

Adult: PO 20 mg tid, may be adjusted q3 day, may use 20- 40 mg tid Renal dose

Adult: PO 20 mg tid or SUS REL 30 mg bid Hepatic dose

Adult: PO 20 mg bid

Available forms: Caps 20, 30 mg; sus rel caps 30, 45, 60 mg; inj 2.5 mg/ml, premixed 20 mg/200 ml, 40 mg/200 ml

Implementation PO route Do not break, crush, chew, or open sus rel caps Give without regard to meals Store in airtight container at room temperature IV route Dilute each 25 mg/240 ml of compatible sol (0.1 mg/ml), give slowly, titrate to patient's response, stable for 24 hr at room temperature, change IV site q30 min Solution compatibilities: D3 W, D5/0.45% NaCl, D5/0.9% NaCl

Y- site compatibilities: Alemtuzumab, amikacin, aminophylline, aztreonam, bivalirudin, butorphanol, calcium gluconate, CARBOplatin, caspofungin, ceFAZolin, ceftizoxime, chloramphenicol, cimetidine, CISplatin, clindamycin, cytarabine, DAPTOmycin, dexmedetomidine, diltiazem, DOBUTamine, DOCetaxel, DOPamine, DOXORubicin hydrochloride, enalaprilat, EPINEPHrine, epirubicin, erythromycin, esmolol, famotidine, fenoldopam, fentaNYL, gentamicin, hydrocortisone, HYDROMorphone, labetalol, lidocaine, linezolid, LORazepam, magnesium sulfate, mechlorethamine, methylPREDNISolone, metroNIDAZOLE, midazolam, milrinone, morphine, nafcillin, nesiritide, nitroglycerin, nitroprusside, norepinephrine, octreotide, oxaliplatin, oxytocin, palonosetron, penicillin G potassium, potassium chloride/phosphate, quinupristin- dalfopristin, ranitidine, rocuronium, tacrolimus, tirofiban, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vasopressin, vecuronium, vinCRISine, voriconazole, zoledronic acid Y- site incompatibilities: Amphotericin B liposome/lipid complex, ampicillin, ampicillin/sulbactam, cefepime, cefoperazone, ertapenem, fluorourecal, furosemide, methotrexate, micafungin, pantoprazole, PEMETrexed, thiopental, thiotepa, tigecycline

Adverse Effects

CNS: Headache, dizziness, anxiety, depression, confusion, paresthesia, somnolence, flushing

CV: Edema, bradycardia, hypotension, palpitations, pulmonary edema, chest pain, tachycardia, increased angina, arrhythmias, CHF

GI: Nausea, vomiting, gastric upset, constipation, hepatitis, abdominal cramps, dry mouth, sore throat

GU: Nocturia, polyuria

INTEG: Rash, infusion site discomfort, Stevens- Johnson syndrome

MISC: Blurred vision, flushing, sweating, SOB, impotence

Pharmacokinetics

Absorption: Well absorbed (PO); bioavailability poor

Distribution: Unknown

Metabolism: Liver, extensively

Excretion: Kidneys 60%, feces 35%

Half-life: 2-5 hr

Pharmacodynamics

PO: Onset ½ hr, Peak 1-2 hr, Duration 8 hr PO SUS

REL: Onset Unknown, Peak 2-6 hr, Duration 10-12 hr

Interactions

Individual drugs

Alcohol: increased hypotension CarBAMazepine, cycloSPORINE, prazosin, propranolol, quiNIDine: increased risk of toxicity

Cimetidine: increased niCARdipine effects Digoxin, quiNIDine, theophylline: increased effects

Rifampin: decreased antihypertensive effect

Drug classifications Antihypertensives, neuromuscular blocking agents, nitrates: increased hypotension

NSAIDs: decreased antihypertensive effect

Drug/herb Ginkgo, ginseng, hawthorn: increased effect Ephedra, melatonin, St. John's wort, yohimbe: decreased effect

Drug/food Grapefruit juice: increased hypotensive effect

Drug/lab test

Increased: LFTs

Decreased: potassium (IV), phosphate, platelets

Nursing Considerations

Assessment Assess fluid volume status (I&O ratio) and record weight, color, quality, and specific gravity of urine, skin turgor, adequacy of pulses, moist mucous membranes, bilateral lung sounds, peripheral pitting edema; dehydration symptoms of decreasing output, thirst, hypotension, dry mouth, and mucous membranes should be reported Monitor for

CHF: weight gain, crackles, jugular venous distention, dyspnea

Hyperpension: assess for decreasing B/P; salt in diet, smoking, exercise, diet, weight, monitor B/P often Assess anginal pain: intensity, location, duration, alleviating factors Monitor potassium, renal/liver function tests, periodically

Patient/family education Advise patient to avoid hazardous activities until stabilized on product and dizziness is no longer a problem Instruct patient to limit caffeine consumption; to avoid alcohol and OTC products unless directed by a prescriber, to take without regard to food, avoid high- fat foods, to swallow sus rel product whole

Hypertension: instruct patient to comply with all areas of medical regimen: diet, exercise, stress reduction, product therapy Instruct patient to notify prescriber of irregular heartbeat, shortness of breath, swelling of feet and hands, pronounced dizziness, constipation, nausea, hypotension, change in severity/pattern/incidence of angina Teach patient to use medication as directed even if feeling better; may be taken with other cardiovascular products (nitrates, β - blockers) Teach patient to take medication exactly as prescribed Advise patient to contact prescriber if anginal attacks continue or become worse

Evaluation

Positive therapeutic outcome: Decreased angina attacks, Decreased B/P TREATMENT OF

OVERDOSE: Defibrillation, atropine for AV block, vasopressor for hypotension

Reference

Mosby's Drug Guide; Davis Drug Guide

Need clinical tools for this drug?

Save notes, bookmark this drug, and run formula method (desire over have) dosage calculations all inside the KosPharm Dashboard.

One-time payment. No subscription. No recurring charges.

Sign in to Get Full Access